Phase 2 Clinical Platform Trial Investigating Multiple Therapeutic Options for the Treatment of Hospitalized Patients with Acute Respiratory Distress Syndrome (ARDS)
Latest Information Update: 28 Nov 2024
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Paridiprubart (Primary) ; Vilobelimab (Primary)
- Indications Respiratory distress syndrome
- Focus Therapeutic Use
- Sponsors Biomedical Advanced Research and Development Authority; PPD
- 28 Nov 2024 New trial record